Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K9PC
|
|||
| Drug Name |
AG-881
|
|||
| Synonyms |
Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop
Click to Show/Hide
|
|||
| Indication | Glioma [ICD-11: 2A00.0] | Phase 3 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2] | ||
| Company |
Agios Pharmaceuticals Cambridge, MA Celgene Summit, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H13ClF6N6
|
|||
| Canonical SMILES |
CC(C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)NC(C)C(F)(F)F
|
|||
| InChI |
1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1
|
|||
| InChIKey |
QCZAWDGAVJMPTA-RNFRBKRXSA-N
|
|||
| CAS Number |
CAS 1644545-52-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Isocitrate dehydrogenase (IDH) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| 2-Oxocarboxylic acid metabolism | ||||
| Biosynthesis of amino acids | ||||
| Peroxisome | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | TCA Cycle | |||
| The citric acid (TCA) cycle and respiratory electron transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04164901) Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.